TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27261998

Group type: EXPERIMENTAL
Intervention: Ayurvedic herbal compound preparation (Murraya koenigii, Punica granatum, Curcuma longa), administered as a decoction twice daily for 4 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo, administered as ground powders for 4 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ayurvedic herbal compound preparation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 25764956

Group type: EXPERIMENTAL
Intervention: Silver-containing hydrofiber (SCH) dressing (Aquacel Ag)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Microorganism-binding (MB) dressing (Cutimed Sorbact)
Number of subjects: 40
Study: 23030822

Group type: EXPERIMENTAL
Intervention: Vessel-sealing device (VSD)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional technique (group 1)
Number of subjects: 120
Study: 21114863

Group type: EXPERIMENTAL
Intervention: General practice‐based intervention to assess and manage unmet needs of caregivers.
Number of subjects: 520

Group type: COMPARATOR
Intervention: Usual care for caregivers.
Number of subjects: 520
Study: 17928573

Group type: EXPERIMENTAL
Intervention: Risperidone augmentation (0.25-1 mg)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo augmentation
Number of subjects: 93
Study: 16299352

Group type: EXPERIMENTAL
Intervention: MCT/LCT emulsion (1:1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: LCT emulsion
Number of subjects: 12
Study: 12571482

Group type: EXPERIMENTAL
Intervention: Mixture ratio of local bone to AWGC granules 2:1
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Mixture ratio of local bone to AWGC granules 1:1
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Mixture ratio of local bone to AWGC granules 1:2
Number of subjects: 35
Study: 10998025

Group type: EXPERIMENTAL
Intervention: Nasal beclomethasone (400 microgram/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 8838964

Group type: EXPERIMENTAL
Intervention: Peroral amoxicillin 0.75 g 3 times daily (n = 50)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo (n = 56)
Number of subjects: 106
Study: 1627419

Group type: EXPERIMENTAL
Intervention: Modified radical mastectomy or partial mastectomy plus radiation therapy
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 465
Study: 6476838

Group type: EXPERIMENTAL
Intervention: Mitoxantrone at dosages of 2 to 4 mg/m2 with a 5‐day schedule or 6 to 12 mg/m2 with a one day schedule, repeating at 4‐week intervals
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 33
Study: 31206579

Group type: EXPERIMENTAL
Intervention: Vida PURA intervention (personalized feedback, motivational interviewing, referral to services)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (information about local substance use treatment services)
Number of subjects: 121
Study: 29677524

Group type: EXPERIMENTAL
Intervention: Community based Depression Intervention Programme (ComDIP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 60
Study: 26945358

Group type: EXPERIMENTAL
Intervention: 5% human albumin (HA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lactated Ringer solution (LR)
Number of subjects: 40
Study: 25091093

Group type: EXPERIMENTAL
Intervention: Orbital atherectomy plus balloon angioplasty (OA + BA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Balloon angioplasty alone (BA)
Number of subjects: 50
Study: 21052672

Group type: EXPERIMENTAL
Intervention: MicroRNA profiles in patients with systemic scleroderma (SSc)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Healthy control individuals
Number of subjects: 6
Study: 19155234

Group type: EXPERIMENTAL
Intervention: DAS-driven therapy (group A)
Number of subjects: 435

Group type: COMPARATOR
Intervention: Routine care (group B)
Number of subjects: 435
Study: 17698144

Group type: EXPERIMENTAL
Intervention: Topical antimicrobial scrub with 4% chlorhexidine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal hygiene (soap and water)
Number of subjects: 100
Study: 16361166

Group type: COMPARATOR
Intervention: Bupivacaine (0.75% 6 mg, diluted to 2 ml with distilled water)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bupivacaine and Levobupivacaine
Number of subjects: 60
Study: 12099982

Group type: EXPERIMENTAL
Intervention: Tacrolimus (dosage not specified)
Number of subjects: 22
Study: 10641952

Group type: EXPERIMENTAL
Intervention: 0.625mg of conjugated equine estrogens plus 2.5mg of medroxyprogesterone daily (Prempro)
Number of subjects: 2763

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2763
Study: 7772614

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MAOIs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective MAO-A inhibitors (moclobemide, brofaromine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluvoxamine (double-blind placebo-controlled study)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MSH/ACTH analog Org 2766
Number of subjects: 0
Study: 2304788

Group type: EXPERIMENTAL
Intervention: Child alone with no parent participation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Mother and child treated in the same session
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Mother and child treated in separate but concurrent session
Number of subjects: 36

Group type: COMPARATOR
Intervention: N/A (control group not explicitly defined)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: N/A (secondary analysis)
Number of subjects: 36
Study: 7388537

Group type: EXPERIMENTAL
Intervention: Milk consumption
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iron supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Milk of Zebu cattle
Number of subjects: 0
Study: 31865631

Group type: EXPERIMENTAL
Intervention: Personalised action plan including the COPD Assessment Test (CAT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 75
Study: 30981585

Group type: EXPERIMENTAL
Intervention: Second generation antipsychotics (SGAs) - haloperidol, flupentixol
Number of subjects: 136

Group type: COMPARATOR
Intervention: First generation antipsychotics (FGAs) - aripiprazole, olanzapine, quetiapine
Number of subjects: 136
Study: 28834469

Group type: EXPERIMENTAL
Intervention: Intensive systolic blood-pressure control (target, <120 mm Hg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard systolic blood-pressure control (target, <140 mm Hg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive systolic blood-pressure control
Number of subjects: 0
Study: 25689936

Group type: EXPERIMENTAL
Intervention: Tolvaptan 7.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23513277

Group type: EXPERIMENTAL
Intervention: 8-Hz stroboscopic illumination
Number of subjects: 18

Group type: COMPARATOR
Intervention: nonstroboscopic condition
Number of subjects: 18
Study: 21534834

Group type: EXPERIMENTAL
Intervention: Choice of target behavior (choice condition)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No choice of target behavior (assigned condition)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Self-management skills training
Number of subjects: 60

Group type: COMPARATOR
Intervention: No self-management skills training
Number of subjects: 60
Study: 18794865

Group type: EXPERIMENTAL
Intervention: Etoposide and G-CSF
Number of subjects: 55

Group type: COMPARATOR
Intervention: Etoposide, G-CSF and rituximab
Number of subjects: 55
Study: 16931805

Group type: EXPERIMENTAL
Intervention: Graphic instructions for missed pill guidance
Number of subjects: 864

Group type: COMPARATOR
Intervention: Text-only instructions for missed pill guidance
Number of subjects: 864

Group type: COMPARATOR
Intervention: Complex instructions (both 21- and 28-day versions)
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Simplified instructions
Number of subjects: 864
Study: 15207943

Group type: EXPERIMENTAL
Intervention: CCK-4 (20 microg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 11026992

Group type: EXPERIMENTAL
Intervention: Local contrast enhancement
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Histogram equalization
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control images
Number of subjects: 12
Study: 9460867

Group type: EXPERIMENTAL
Intervention: Russian vaccine 'Combiotech'
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: American vaccine 'H-B-Vax II'
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both vaccines (schedule 0-1-2 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both vaccines (schedule 0-1-6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Children receiving only the vaccines
Number of subjects: 0
Study: 8404168

Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline (TE)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Ipratropium bromide (IB)
Number of subjects: 14
Study: 2877596

Group type: EXPERIMENTAL
Intervention: Vecuronium (100 micrograms/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pancuronium (100 micrograms/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Comparison of vecuronium and pancuronium
Number of subjects: 12
Study: 30776537

Group type: EXPERIMENTAL
Intervention: Strong opioids
Number of subjects: 498

Group type: COMPARATOR
Intervention: Previous weak opioid therapy
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 498
Study: 30384498

Group type: EXPERIMENTAL
Intervention: Multidisciplinary team management (multidisciplinary assessments and individual rehabilitation management)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy (ACT)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Control
Number of subjects: 427
Study: 26749026

Group type: EXPERIMENTAL
Intervention: Lidocaine 2%
Number of subjects: 76

Group type: COMPARATOR
Intervention: Saline 0.9%
Number of subjects: 76
Study: 25243960

Group type: EXPERIMENTAL
Intervention: Fuzhenghuayu capsule
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Fuzhenghuayu capsule plus propranolol
Number of subjects: 181

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Fuzhenghuayu capsule alone
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 181
Study: 22983753

Group type: EXPERIMENTAL
Intervention: Community-responsive interventions targeting adults and/or children to promote healthy behaviors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 19841149

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (AQ-AS)
Number of subjects: 41
Study: 17134723

Group type: EXPERIMENTAL
Intervention: Bilateral movement training
Number of subjects: 12

Group type: COMPARATOR
Intervention: Unilateral movement training
Number of subjects: 12
Study: 16359410

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 11963783

Group type: EXPERIMENTAL
Intervention: New perforated PDS foil (0.15 mm thickness)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Titanium dynamic mesh (0.3 mm thickness)
Number of subjects: 0
Study: 9797054

Group type: EXPERIMENTAL
Intervention: Potassium citrate, sodium fluoride, cetylpyridinium chloride mouthrinse
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 90
Study: 7640497

Group type: EXPERIMENTAL
Intervention: Compound salviae miltiorrhizae injection
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study: 2486590

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine + 1 mg butorphanol (Group I)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine + 2 mg butorphanol (Group II)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine + 2 mg morphine (Group III)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.25% bupivacaine alone (Group IV)
Number of subjects: 40
Study: 779383

Group type: EXPERIMENTAL
Intervention: Billroth I gastric resection
Number of subjects: 45

Group type: COMPARATOR
Intervention: Truncal vagotomy and pyloroplasty
Number of subjects: 45
Study: 31369680

Group type: EXPERIMENTAL
Intervention: Temporal muscle thickness (TMT) above the cutoff of 7.2 mm
Number of subjects: 596
Study: 28109962

Group type: EXPERIMENTAL
Intervention: Resuscitation strategies (three different strategies)
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Nonsurvivors (higher levels of Ang-2 and sFLT-1, and lower levels of VEGF)
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: sFLT-1
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Lactate
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Sequential Organ Failure Assessment score
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: sFLT-1 (adjusted for age, presence of cancer, and Charlson comorbidity score)
Number of subjects: 1341
Study: 25412300

Group type: EXPERIMENTAL
Intervention: Home-based exercise program (EX), combining continuous steady-state and interval cycling at various intensities, in combination with unsupervised moderate intensity aerobic activity and conventional diabetic management
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional management alone (CON)
Number of subjects: 40
Study: 23470235

Group type: EXPERIMENTAL
Intervention: Sertaconazole 2% cream applied twice daily for 1 month
Number of subjects: 45

Group type: COMPARATOR
Intervention: Hydrocortisone 1% ointment applied twice daily for 1 month
Number of subjects: 45
Study: 21528627

Group type: EXPERIMENTAL
Intervention: Low-intensity vibration (LIV) at 0.27 +/- 0.11 g; 34 Hz
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Low-intensity vibration (LIV) at 0.44 +/- 0.18 g; 34 Hz
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (able-bodied)
Number of subjects: 17
Study: 18609024

Group type: EXPERIMENTAL
Intervention: Small group exercises based on a personal construct approach
Number of subjects: 32
Study: 16062032

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 0
Study: 11887543

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (group 1)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Compressed air (group 2)
Number of subjects: 111
Study: 11783255

Group type: EXPERIMENTAL
Intervention: Sini Decoction (SND), 25 ml daily from 3 days before operation to the third day after operation.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 40
Study: 8721897

Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) + Lentinan
Number of subjects: 107

Group type: COMPARATOR
Intervention: Didanosine (ddI)
Number of subjects: 107
Study: 2551560

Group type: EXPERIMENTAL
Intervention: Dilevalol (25, 50, and 50 mg bolus injections at 15-minute intervals)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dilevalol
Number of subjects: 16
Study: 391093

Group type: EXPERIMENTAL
Intervention: New lancet with a point length of 1.0 mm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional prick test method
Number of subjects: 0
Study: 31693083

Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block (SGB) treatment
Number of subjects: 113

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 113
Study: 30817018

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 28379017

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Analgosedation (AS)
Number of subjects: 50
Study: 26887208

Group type: EXPERIMENTAL
Intervention: Heat-sensitive moxibustion applied to Guanyuan (GV 4) for 40 min, once daily for (7 +/- 2) days in one menstrual cycle, for 3 menstrual cycles.
Number of subjects: 189

Group type: COMPARATOR
Intervention: Conventional warm sensation moxibustion.
Number of subjects: 189
Study: 22805254

Group type: EXPERIMENTAL
Intervention: Acupressure plus routine care
Number of subjects: 78

Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 78
Study: 22453108

Group type: EXPERIMENTAL
Intervention: Chart-alert sticker ('Do you leak urine?')
Number of subjects: 190

Group type: COMPARATOR
Intervention: No sticker (control group)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Chart-alert sticker
Number of subjects: 190
Study: 19968383

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Antidepressant medication (ADM)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Self-criticism
Number of subjects: 113
Study: 16289676

Group type: EXPERIMENTAL
Intervention: Bio-adhesive 0.2% chlorhexidine gel applied once during surgery
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo gel applied once during surgery
Number of subjects: 103
Study: 15250781

Group type: EXPERIMENTAL
Intervention: Frequency-ordered serial comparison or verification procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Search model extensions
Number of subjects: 0
Study: 12478901

Group type: EXPERIMENTAL
Intervention: rhIL-11 (50 micrograms/kg/d) administered subcutaneously for 14 consecutive days after chemotherapy
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: rhIL-11 during cycle A
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (no IL-11 during cycle B)
Number of subjects: 109
Study: 9468251

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Lansoprazole (all doses)
Number of subjects: 292
Study: 7621277

Group type: EXPERIMENTAL
Intervention: 5 MU of alpha-2b IFN three times per week for 12 months
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 6 MU of alpha-2a IFN three times per week for one year
Number of subjects: 48

Group type: COMPARATOR
Intervention: Untreated patients (control group)
Number of subjects: 48
Study: 2122719

Group type: EXPERIMENTAL
Intervention: Lactase-containing tablets
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 18
Study: 350398

Group type: EXPERIMENTAL
Intervention: Ftorafur with mitomycin C
Number of subjects: 52

Group type: COMPARATOR
Intervention: Ftorafur with methyl-CCNU
Number of subjects: 52
Study: 30377198

Group type: EXPERIMENTAL
Intervention: Epacadostat (IDO1-selective inhibitor) in combination with pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28010051

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25576753

Group type: EXPERIMENTAL
Intervention: Intensified infliximab regimen (5mg/kg every 4 weeks for 12 weeks)
Number of subjects: 42
Study: 23242365

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 21276122

Group type: EXPERIMENTAL
Intervention: 20 mg of lycopene for 12 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 28
Study: 19738090

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) algorithm for antibiotic administration
Number of subjects: 1359
Study: 17375876

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 120

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 120
Study: 15499533

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) at 6.4 mg/kg DHA
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine plus additional artemisinin derivative (DP+) at 12 mg/kg
Number of subjects: 731

Group type: COMPARATOR
Intervention: Mefloquine plus artesunate (MAS3)
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine plus additional artemisinin derivative (DP+)
Number of subjects: 731
Study: 11552664

Group type: EXPERIMENTAL
Intervention: Cladribine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9591811

Group type: EXPERIMENTAL
Intervention: Bath-PUVA-311 nm
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bath-PUVA
Number of subjects: 12
Study: 8148194

Group type: EXPERIMENTAL
Intervention: Acorn nebulizer attached to the Mizer Aerosol Conservation Device (MACD)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Acorn nebulizer and mouthpiece alone
Number of subjects: 12
Study: 2971549

Group type: EXPERIMENTAL
Intervention: Doxazosin (mean final daily dose: 13.1 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31529462

Group type: EXPERIMENTAL
Intervention: APACHE II score
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index (CCI)
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: ASA score
Number of subjects: 885
Study: 29519716

Group type: EXPERIMENTAL
Intervention: 5-month regimen of moxifloxacin, pasiniazid, rifabutin, ethambutol, and pyrazinamide (n = 626)
Number of subjects: 917

Group type: COMPARATOR
Intervention: 8-month regimen of isoniazid, rifampicin, and streptomycin (n = 291)
Number of subjects: 917

Group type: EXPERIMENTAL
Intervention: 5-month regimen for patients with multidrug-resistant TB (MDR-TB)
Number of subjects: 917

Group type: COMPARATOR
Intervention: 8-month regimen for patients with multidrug-resistant TB (MDR-TB)
Number of subjects: 917
Study: 26179561

Group type: EXPERIMENTAL
Intervention: Propofol (P)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Propofol/Remifentanil (PR)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Propofol/Remifentanil/S-Ketamine (PRK)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no anesthesia)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Anesthesia (general)
Number of subjects: 48